I usually steer clear of mouse studies. Mice lie and monkeys exaggerate, some researchers say. But this is another piece to add to the growing pile of evidence that there’s a great big link between multiple sclerosis and the Epstein-Barr virus, and that’s important to help make the case for a connection.
The study, “Epstein Barr virus‐immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice,” was published in the Journal of Medical Virology.
Click here to read the full story.
I’ve tried CBD ointment on my legs and CBD liquid under the tongue. I’ve tried THC blended with CBD. However, I’ve never been comfortable with either. I don’t know what the best dose is, and I don’t want to experiment. I’m also uncomfortable with inconsistent quality control. So, I’d like to see more studies like this one, hoping that it will help create evidence-based guidelines for using cannabis products to treat MS symptoms.
The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other symptoms of multiple sclerosis (MS).
The money, worth about $1.1 million, will support the trial for the next five years, and is part of CIHR’s Integrated Cannabis Research Strategy (ICRS). This initiative, involving several partner institutions, aims to generate strong scientific evidence to support policies and regulations governing the use of cannabis.
Click here to read the whole story.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?